银屑病生物制剂达标治疗专家共识

Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents

银屑病是一种慢性、复发性、炎症性和系统性疾病,给患者带来沉重负担,影响患者生活质量。随着多种生物制剂不断应用于临床,银屑病患者有更多的治疗选择,但综合治疗目标如何评估尚未达成一致意见。达标治疗策略需要考虑多个维度的治疗结果,制定长期管理目标和定期评估治疗情况。本共识根据国内外最新共识及指南、研究数据和临床经验,结合问卷调查和专家组的讨论结果,重点阐述了清除皮损、提高患者生活质量、筛查和管理银屑病共病和保障用药安全性这4个维度的短期和长期银屑病生物制剂治疗的综合管理目标,描述了实施方法、评估时间、治疗监测和方案调整,旨在最大程度实现银屑病全面管理的目标,供临床参考。

Psoriasis is a chronic,recurrent,inflammatory and systemic disease,which places a heavy burden on patients and affects their quality of life.As multiple biologics have been constantly approved for clinical use,there are more effective treatment options for psoriasis patients,but there has been no consensus on what are the comprehensive treatment goals to be reached in China.Treat-to-target approach requires considering treatment outcomes in multiple dimensions,establishing long-term management goals,and assessing treatment outcomes regularly.Based on the latest Chinese and international consensus and guidelines,studies and clinical experience,and combined with results of a questionnaire survey and expert group discussion,this consensus focuses on the short-term and long-term comprehensive management goals on biologics treatment of psoriasis in four dimensions,i.e.,clearing psoriatic lesions,improving the quality of life,screening and managing psoriasis comorbidities,and ensuring medication safety,and describes implementation methods,timing of evaluation,treatment monitoring,and regimen adjustment,aiming to achieve the goal of comprehensive management of psoriasis to the greatest extent,and to provide a reference for clinicians.